FORM	PTO-1449
------	----------

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 2848-39-2	SERIAL NO. 10/776, 827			
APPLICANT HORWITZ et al.				
FILING DATE February 10, 2004	GROUP ART 1646			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
RLi	1	5,364,791	11/15/94	Vegeto et al.	435	320.1	
	2	5,506,102	4/9/96	McDonnell	435	6	
	3	5,683,885	11/4/97	Kieback	435	7.1	\
	4	5,759,785	6/2/98	Tsai et al.	435	7/1	
	5	5,770,176	6/23/98	Nargessi	424	1.49	\
	6	5,808,139	9/15/98	Pathirana et al.	560	138	
1	7	5,935,934	8/10/99	Vegeto et al.	514	44	
RLi	8	5,945,279	8/31/99	O'Mailey et al.	435	6	

FOREIGN PATENT DOCUMENTS

						SUB	TRANSLATION	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO
RLi	9	WO 98/05679	2/12/98	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

RLi	10	Bethea et al., <i>Endocrinology</i> , 139(2):677-687 (1998)
	11	Fujimoto et al., J. Steroid Biochem. Molec. Biol., 62(5/6):449-454 (1997)
	12	Graham et al., Cancer Res., 55:5063-5068 (1995)
	13	Graham et al., Cancer Res., 52:593-602 (1992)
Ų.	14	Groshong et al., Mol. Endocrinol., 11:1593-1607 (1997)
	15	Horwitz et al., J. Biol. Chem., 253(22):8185-8191 (1978)
	16	Kester et al., J. Biol. Chem., 272(26):16637-16643 (1997)
V	17	Lydon et al., Genes & Devel., 9:2266-2278 (1995)
RLi	18	McDonnell et al., J. Biol. Chem., 269(16):11945-11949 (1994)

EXAMINER	Ruidiang L.	DATE CONSIDERED	10 6 2004
ACMANNIED. 1-7	Airlift and a second and address and after	in in any formance with MACD 600: Dr	caw line through citation if not in conformance and

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 2848-39-2	SERIAL NO. 10/176,827		
APPLICANT HORWITZ et al.			
FILING DATE	GROUP ART 646		

RLI	19	McGowan et al., Mol. Endocrinol., 13:1657-1671 (1999)
	20	Mote et al., J. Clin. Endocrinol. Metab., 84:2963-2971 (1999)
21 Mulac-Jericevic et al., Science, 289:1751-1754 (2000)		Mulac-Jericevic et al., Science, 289:1751-1754 (2000)
	22	Nishida et al., Biochem. Biophys. Res. Comm., 241:258-263 (1997)
	23	Richer et al., J. Biol. Chem., 273(47):31317-31326 (1998)
	24	Richer, <i>ENDO</i> , p. 341 (2000) (Abstract #1411)
	25	Sartorius et al., Cancer Res., 54:3868-3877 (1994)
	26	Sartorius et al., Mol. Endocrinol., 8:1347-1360 (1994)
	27	Shyamala et al., <i>Proc. Natl. Acad. Sci. USA</i> , 95:696-701 (1998)
	28	Shyamala et al., PNAS, 97(7):3044-3049 (2000)
	29	Tian et al., PNAS, 97(26):14358-14363 (2000)
	30	Tung et al., Mol. Endocrinol., 7:1256-1265 (1993)
RLi	31	Vegeto et al., Mol. Endocrinol., 7:1244-1255 (1993)

EXAMINER

Rundiang L.

DATE CONSIDERED

10/6/2004